Trial Profile

A Phase II Trial of High-Dose 90Y-Ibritumomab Tiuxetan (Anti-CD20) Followed by Fludarabine and Low-Dose Total Body Irradiation and HLA-matched Allogeneic Hematopoietic Transplantation for Patients With Relapsed or Refractory Aggressive B-cell Lymphoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 07 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibritumomab tiuxetan (Primary) ; Ciclosporin; Fludarabine; Ibritumomab tiuxetan; Mycophenolate mofetil; Rituximab
Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
Focus Therapeutic Use

29 Aug 2019 Planned End Date changed from 24 Sep 2022 to 1 Sep 2021.
29 Aug 2019 Planned primary completion date changed from 24 Sep 2019 to 24 Jul 2020.
29 Aug 2019 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com